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a b s t r a c t
Neuropathic pain is commonly associated with affective disorders such as anxiety and depression. We
have previously characterised a rodent model of HIV, anti-retroviral-associated neuropathy in which rats
develophypersensitivity to apunctatemechanical stimulus anddisplay anxiety-like behaviour in theopen
ﬁeld paradigm. To assess the potential of this behavioural paradigm for the assessment of pain related
co-morbidities in rodent models of pain, here we test the sensitivity of this anxiety-like behaviour to theeywords:
europathic pain
ain comorbidity
pen ﬁeld activity
IV neuropathy
abapentin
analgesic agents gabapentin and morphine in comparison to the known anxiolytic drug diazepam. We
found that gabapentin (30mg/kg, i.p.) and morphine (2.5mg/kg, i.p.), which reduce mechanical hyper-
sensitivity in these rats, signiﬁcantly reduces measures of thigmotaxis in the open ﬁeld. The effect of
gabapentin and morphine did not differ signiﬁcantly from diazepam (1mg/kg, i.p.). This study high-
lights the potential use of this rodent model and behavioural paradigm in the validation of the affective
component of novel analgesic pharmacological targets and elucidation of underlying pathophysiological
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mechanisms.
hronic neuropathic pain arises as a direct consequence of a lesion
r disease affecting the somatosensory system [34]. For exam-
le, direct nerve trauma; diseases such as diabetes and HIV; and
herapies including anti-retroviral- and chemo-therapy are some-
imes associated with spontaneous pain and occasionally evoked
ain associated with signs of sensory gain such as hyperalgesia
r allodynia. Moreover, there is signiﬁcant co-morbidity between
europathic pain and neuropsychiatric disorders, including anxi-
ty and depression [5,26,33]. The high prevalence and deleterious
mpact of affective illness in chronic pain sufferers is well recog-
ised [12,22,30,36] yet there is little evidence to support common
athophysiological mechanisms [22,35].
Rodent models have proven valuable in identifying patho-
hysiological mechanisms and therapeutic targets for emotional
isorders [4]. Extensive research has characterised the behavioural
henotypes of an array of rodent models of neuropathic pain
6,20,32,39]. However, the majority of such studies rely on mea-
ures of evoked withdrawal responses to identify hypersensitivity
tates and therefore reveal little, if any, information regarding emo-
ional or subjective aspects of pain that are so commonly observed
n the clinic and measured in clinical trials [9]. Recently how-
ver, a number of studies have begun to tackle this problem by
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easuring pain and anxiety-like behaviour in rodent models of
europathic pain; combining hind pawwithdrawal tests with anx-
ety paradigms such as the open ﬁeld and elevated plus maze
15,16,23,29,38,37,40]. These data suggest that such behavioural
aradigms are useful for the assessment of pain related co-
orbidities in rodent models and may therefore prove useful in
he elucidation of underlying pathophysiological mechanisms and
alidate potential pharmacological analgesic targets.
We have previously characterised a rodent model of anti-
etroviral-associated neuropathy in which rats develop hypersen-
itivity to a punctate mechanical stimulus and display anxiety-like
ehaviour in the open ﬁeld paradigm [38]. Gabapentin and mor-
hine are effective analgesic agents in human neuropathic pain
onditions [10,17], and are known to reduce mechanical hyper-
ensitivity in various models of neuropathic pain [15,38,37]. The
urrent study assesses the effect of these analgesic agents on the
nxiety-like behaviour in anti-retroviral-treated rats in compari-
on to theknownanxiolytic drugdiazepam. This studyaims todraw
omparisons between the anti-hypersensitivity/analgesic and anx-
olytic properties of these drugs in an effort to correlate pain and
o-morbidity behaviour in models of neuropathic pain. Correla-
Open access under CC BY licenseions between such behavioural traits would highlight the use of
uch models and behavioural measures in future research.
All experiments conformed to the British Home Ofﬁce Reg-
lations and IASP guidelines [41]. Male Wistar rats weighing
00–250g were used for all experiments (B&K, Hull, UK) and were
1 ience Letters 448 (2008) 153–156
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Fig. 1. The development of hind paw reﬂex sensitivity to punctatemechanical stim-
uli in rats treated with ddC. Hind paw withdrawal thresholds to an electronic von
Frey device measured following treatment with 50mg/kg ddC ( n=60) or saline
sham control ( n=10). Data is shown at baseline and at time of peak hypersensitiv-
ity (days 19–21). Statistical signiﬁcance of differences between groups (§p≤0.05)
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oused in a temperature-controlled environment, maintained on a
4:10h light–dark cycle (experiments were performed during the
ight phase) and provided with feed and water ad libitum.
Animalswere injected intraperitoneallywith 0.5ml of ddC solu-
ion (50mg/kg in sterile saline; Sigma–Aldrich, Poole, UK) or as a
ontrol, sterile saline three times aweek for up to 3weeks (Monday,
ednesday, Friday) [38,40].
Testing of hind paw reﬂex behaviour was performed as
escribed previously [15,38,37,40]. Brieﬂy, the threshold for hind
aw withdrawal in response to punctate mechanical stimulation
as measured in conscious animals using an electronic “von Frey”
evice [27] of 0.5mm2 probe tip area (Somedic Sales AB, Sweden).
Baseline measurements were obtained for all rats over the
ourse of a week prior to start of ddC treatment. Hind paw
eﬂex thresholds were then assessed by a “blinded” observer. The
hreshold value at each time point tested was calculated as the
ean± S.E.M.
Between days 19 and 21 following the ﬁrst ddC injection; rats
ith established hind paw hypersensitivity to punctate mechan-
cal stimulation (a change of at least 30% from baseline) were
andomised into treatment group and administered intraperi-
oneally with either; gabapentin (Pﬁzer Ltd.; 30mg/kg in saline),
orphine sulphate (Sigma–Aldrich 2.5mg/kg, in saline) [doses
s previously described [15,38,37]], diazepam [Sigma–Aldrich;
mg/kg [31] in 1:2mix of ethanol (absolutemolecular grade; VWR,
oole) and cremophor EL (Univar; Essex, UK)] or vehicle (sterile
aline or ethanol/cremaphor). Each animal was only used once
or this experiment. 40min post-injection, rats were placed into
100 cm×100 cm arena illuminated to 4 lx with a deﬁned inner
one of 40 cm×40 cm. Locomotion of the rats within the arena
as tracked over 15min using a Sanyo VCB 3372 high-resolution
onochrome camera (Tracksys, Notts, UK) and stored and analysed
ith Ethovision software v.3 (Tracksys) as described previously
15,38,37]. The total distance moved, time spent in the inner zone
nd the number of entries into the inner zone were calculated
nd displayed as the mean± S.E.M. For all experiments, the exper-
menter was “blinded” to drug treatments received.
Sigmastat version 2.03 (SPSS Inc., Surrey, UK) was used to deter-
ine the presence of statistically signiﬁcant differences (minimum
≤0.05) throughout the study. All groups were compared using a
ruskall–Wallis one-way analysis of variance (ANOVA)withDunn’s
ll pairwise or multiple comparisons vs. control post hoc analysis.
In line with previous studies [38], rats treated with ddC
eveloped a signiﬁcant (p≤0.05) hypersensitivity to punctate
echanical stimulation by days 19–21 (33.2±1.9 g) as compared to
aseline (49.3±1.9 g) or sham controls (48.6±2.3 g) (Fig. 1). Rats
hat had developed at least 30% change from baseline (n=60; eight
xcluded) were then randomised into groups for the open ﬁeld
est.
At the time of peak mechanical hypersensitivity, ddC-treated
ats (n=12) receiving no injection prior to the open ﬁeld test
howed no signiﬁcant difference in the total distance moved
6461±542 cm) vs. sham control rats (7503±568 cm) (Fig. 2A),
uggesting a lack of overt motor deﬁcit. However, ddC-treated rats
isplayed a signiﬁcantly (p≤0.01) reduced number of entries into
he inner zone (3.9±0.8 vs. 10±2.0) (Fig. 2B) and time spent in
he inner zone (10.7±2.1 s vs. 15.9±1.6 s) (Fig. 2C) as compared to
ham control animals (n=9). This is characteristic of thigmotaxis,
hought to be associated with anxiety-like behaviour.
To test the sensitivityof the thigmotacticbehaviour toa standard
nxiolytic drug, we assessed the effect of diazepam on thigmotac-
ic behaviour in ddC-treated rats. When administered 40min prior
o testing, diazepam (n=9; 1mg/kg, i.p.) signiﬁcantly (p≤0.05)
ncreased thenumber of entries into (6.2±0.5 vs. control; 2.5±0.3)
Fig. 2B) and time spent in the inner zone (18.0±1.7 vs. control;
b
e
c
sas determined by a Kruskall–Wallis one-way analysis of variance (ANOVA) with
unn’s all pairwise multiple comparisons post hoc analysis where. Each value is the
ean± S.E.M.
.0±1.4 s) (Fig. 2C) of the open ﬁeld as compared to vehicle control
reatment.
We have previously demonstrated that gabapentin (30mg/kg,
.p.) and morphine (2.5mg/kg, i.p.) signiﬁcantly reverse mechani-
al hypersensitivity displayed by ddC-treated rats [38]. Therefore
o assess the association between hypersensitivity and anxiety
ehaviour in ddC-treated rats we assessed the effect of these
rugs on thigmotactic behaviour in the open ﬁeld. Gabapentin
n=9; 30mg/kg, i.p.) and morphine (n=11; 2.5mg/kg, i.p.) sig-
iﬁcantly (p≤0.05) increased the number of entries into the
nner zone (gabapentin: 6.1±0.7; morphine: 8.2±1.7; control:
.5±0.3) (Fig. 2B) and time spent in the inner zone (gabapentin:
2±3.9 s; morphine: 23.9±5.4 s; control: 9.0±1.4 s) (Fig. 2C) of
he open ﬁeld arena as compared to vehicle control treatment.
he effect of gabapentin andmorphine was not signiﬁcantly differ-
nt from diazepam for either parameter. Furthermore, none of the
rugs signiﬁcantly altered the total distance moved (gabapentin:
896±563;morphine:6702±418;diazepam:5086±716; control:
099±318 cm) (Fig. 2A), suggesting a lack of overt motor effects by
ny treatment. As there was no signiﬁcant difference between val-
es for saline vehicle control (n=10) or cremaphor/ethanol vehicle
ontrol (n=9) prior to open ﬁeld testing, the data for these groups
as been pooled.
Neuropathic pain is commonly associated with affective disor-
ers suchas anxiety anddepression [5,26,33]. Previous studieshave
emonstrated measures of anxiety-like behaviour in rodent mod-
ls of neuropathic pain [15,38,37], yet few have determined if the
ypersensitivity indicative of a pain state is actually correlatedwith
he anxiety behaviour observed. Here we have demonstrated that
ats treated with the antiretroviral ddC display behaviour associ-
ted with mechanical hypersensitivity and anxiety both of which
an be targeted by the analgesic agents, gabapentin andmorphine.
The open ﬁeld paradigm is based upon the rodent’s conﬂict
etween an innate aversion to exposed spaces and a tendency to
xplore novel environments [4]. Reduced exploratory behaviour
haracterised by thigmotactic (wall-hugging) behaviour is clas-
ically interpreted as anxiety-like behaviour. In support of the
V.C.J. Wallace et al. / Neuroscience Letters 448 (2008) 153–156 155
Fig. 2. Gabapentin, morphine and diazepam attenuate thigmotactic behaviour of ddC-treated rats in an open ﬁeld arena. (A) The total distance moved within the open ﬁeld
arena (1m×1m) was assessed over 15min and is not signiﬁcantly altered in ddC-treated rats as compared to saline controls or in rats treated with drug or vehicle control
40min prior to the open ﬁeld test (number of rats in each group shown in brackets). (B) The number of entries into the inner zone (40 cm×40 cm) and (C) time spent in
the inner zone of the open ﬁeld arena was signiﬁcantly reduced in ddC-treated rats vs. sham controls. This reduction was signiﬁcantly attenuated by gabapentin (30mg/kg),
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iorphine (2.5mg/kg) and diazepam (1mg/kg) when administered 40min prior to t
§p≤0.01) or drug treatment groups and the vehicle control group (*p≤0.05) was
ultiple comparisons vs. control post hoc analysis. As the ddC+vehicle groups did
alue is the mean± S.E.M.
ypothesis that thigmotactic behaviour in our rat model of
ntiretroviral related neuropathy is anxiety-like, we have demon-
trated it’s susceptibility to the benzodiazepine class of anxiolytic;
iazepam. Of interest, a recent study [29] demonstrated that
nxiety-like behaviour displayed by neuropathic rats in an alterna-
ive behavioural paradigm, the elevated plusmaze,was normalised
y the benzodiazepine, midazolam, without any analgesic effect.
lthough slightly different drugs with respect to receptor targets,
his suggests that diazepam is unlikely to be acting as an analgesic
n this study but rather as an anxiolytic.
Gabapentin has been shown to be efﬁcacious in reducing mea-
ures of pain-like behaviour in rodent models of pain [1,7,8] and is
known analgesic in human neuropathic pain conditions [10,17],
ncluding HIV-neuropathy in the short term [14]. Morphine atten-
ates hypersensitivity in rodent neuropathy models [2,21] and
vidence is accumulating to suggest that opioids relieve symptoms
f human neuropathic pain of peripheral origin [10,17]. We have
reviously demonstrated that gabapentin and morphine reverse
ypersensitivity in ddC-treated rats [38] suggesting that the hyper-
ensitivity displayed in this model may prove as a useful measure
or testing the clinical utility of novel analgesic agents in the
uture. Our present data demonstrates that gabapentin and mor-
hine also reverse thigmotactic behaviour. Together with the effect
f diazepam, these data suggests that the thigmotactic behaviour
bserved in ddC-treated rats is indicative of an anxiety-like state
hat is associated with the pain state. In line with this, a pre-
ious study by Roeska et al. [29] demonstrated that gabapentin
m
p
c
s
c. The statistical signiﬁcance of differences between ddC treated and sham animals
ined using a Kruskall–Wallis one-way analysis of variance (ANOVA) with Dunn’s
ffer signiﬁcantly from each other, this data was pooled for graphical display. Each
nd morphine, at the doses used in this study, reverse anxiety-
ike behaviour in rodent neuropathic pain models without such
ffect in sham animals. Therefore, it would seem that in non-
europathic rats, gabapentin and morphine drugs do not possess
nxiolytic properties at these doses. Furthermore, in spite of pre-
ious evidence in which morphine reduces motility in rats in
imilar behavioural paradigms, in this study and the study by
oeska et al. [29], no negative effect of morphine on motility was
bserved. These data show that the effect of morphine is variable
epending on the dose, animal model and route of administra-
ion employed. Our data therefore supports our hypothesis that the
nxiety-behaviour measured in this study is associated with the
ain state of the animal and is susceptible to analgesic compounds.
vidence suggests that different rodent behavioural tests, espe-
ially of anxiety, are likely qualitatively different from one another
nd may well model different aspects of the human conditions
3,4,18]. Therefore, in light of our results and the study by Roeska et
l. [29], we feel that it will be useful to extend these data to other
easures of anxiety- and also depression-related behaviours.
Until now, very little preclinical research in rodents has been
ble to test much more than basic measures of hypersensitiv-
ty. In contrast, clinical studies encompass a greater range of
easures including subjective, qualitative and psychological com-
onents [24,25,28] which reﬂect the true extent of symptoms of
hronic pain. Therefore, to draw closer parallels with the clinical
cenario, there is a great need for a larger variety of tests pre-
linically. In such, further utilisation of clinically relevant rodent
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odels such as those recently characterised to investigate mech-
nisms of varicella-zoster virus-associated neuropathy [11,13,15],
IV-neuropathy [38,37] and as in this case, drug induced neuropa-
hy [19,38] in combination with integrative behavioural measures
uch as the open ﬁeld paradigm will undoubtedly prove useful for
he elucidation of mechanisms of chronic pain and co-morbidities
nd ultimately efﬁcacious therapeutic targets.
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